Regenerative & personalized medicine

Electroceutical devices that treat disease by electrically stimulating nerves rather than with drugs — vagus and splenic nerve neuroimmune modulation, AI-personalized spinal cord stimulation, hypoglossal nerve stimulation and implantable neuromodulation for paralysis and neurological disease: SetPoint Medical, Nevro Corp and Inspire Medical Systems in the US, Galvani Bioelectronics and Onward Medical in Europe, and PINS Medical in China.

The engineering of medical devices that interface with the body — orthopedic, cardiovascular and neuro implants — sold as capital robotic systems, per-procedure implants and regulated biomaterials under FDA, EU MDR and NMPA oversight.

Bio-inspired surgical adhesives, sealants and hemostatic gels that bond, seal or stop bleeding in wet tissue environments where conventional sutures and staples struggle — drawing on biological adhesion mechanisms such as mussel/oyster adhesive proteins: Tissium in France, Cresilon and Brij Medical in the US, and Adhesys Medical in Germany.

Prosthetic devices that replace a lost limb's function through AI-driven control, touch sensing and direct skeletal attachment — dexterous touch-sensing hands, AI neural prosthetic control, myoelectric pattern recognition and osseointegrated prostheses: Psyonic, Atom Limbs and Coapt in the US, Ottobock and Integrum in Europe, and BrainCo (BrainRobotics) in China.

Dry-electrode EEG wearables — headbands, earbuds and sleep masks — that read brainwave activity without gel or clinical setup, using on-device AI artifact removal and neurofeedback training to support meditation, focus and sleep, regulated as general wellness devices rather than medical BCI.

Software-as-medical-device treatments that deliver a regulator-cleared clinical intervention rather than general wellness support — prescription digital therapeutics for ADHD, insomnia, anxiety and depression, musculoskeletal digital rehabilitation and pediatric autism intervention: Akili Interactive, Big Health and Click Therapeutics in the US, Kaia Health in Germany, and ALSOLIFE in China.

Cell-derived nanoscale vesicles (30-150 nm) used as native regenerative-medicine agents or engineered as biocompatible drug-delivery vehicles for RNA, protein and gene-editing cargo, crossing biological barriers artificial lipid nanoparticles cannot.

Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive endometriosis testing, ovarian-longevity therapeutics, vaginal-microbiome LBPs and cfDNA prenatal screening, under FDA, EU IVDR/EMA and NMPA oversight.

Selectively clearing senescent 'zombie' cells or suppressing their inflammatory secretome to treat age-related disease at its molecular root, rather than one downstream condition at a time.

Deriving functional human eggs and sperm entirely outside the body from reprogrammed stem cells, aimed at reversing absolute infertility and enabling genome-corrected embryos.

Surface-engineering and coating technologies that govern how a catheter, guidewire, stent or implant actually meets living tissue — hydrophilic lubricious coatings, bioactive anticoagulant polymer layers, and drug-eluting coating systems — spanning Formacoat, Biocoat and Integer Holdings in the US, Freudenberg Medical and DSM Biomedical in Europe, and Sino Medical Sciences Technology in China.

Brain–computer interfaces that read motor and speech cortex activity and decode intent into text, synthesized voice or robotic movement — spanning invasive intracortical arrays, endovascular stent-electrodes, semi-invasive ECoG and non-invasive EEG, under FDA IDE trials, EU MDR and NMPA oversight.

Additive manufacturing of living cells and biomaterials to construct functional tissue models and transplantable organs.

Transient expression of Yamanaka reprogramming factors to reverse epigenetic markers of cellular aging without erasing cell identity — OSK gene therapy, AI-discovered reprogramming payloads and safer single-gene rejuvenation targets: Altos Labs, Retro Biosciences, NewLimit and Life Biosciences in the US, Shift Bioscience in the UK, and JingTong Life in China.

Computational patient models and virtual trial simulations used to reduce, accelerate or de-risk clinical development — AI-generated synthetic control arms, physiologically-based pharmacokinetic modeling, preclinical-to-clinical translation AI and causal-AI virtual patient simulation: Unlearn.AI, Certara and VeriSIM Life in the US, and Novadiscovery (Nova In Silico) in France.

Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.

Dietary recommendations tailored to an individual's gut microbiome, DNA and real-time glucose response, delivered as test-kit subscriptions, AI food scores and custom-formulated supplements.

Transplanting organs from multiplex gene-edited pigs into humans to address the chronic shortage of donor organs, now moving from expanded-access compassionate cases into FDA-cleared clinical trials.